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Abstract In order to explore how the choice of different
study designs could inﬂuence the risk estimates, a case–
crossover and case–time–control study were carried out and
their outcomes were compared with those of a traditional
case–control study design that evaluated the association
between the exposure to psychotropic medications and the
risk of having a motor vehicle accident (MVA). A record-
linkage database availing data for 3,786 cases and 18,089
controls during the period 2000–2007 was used. The study
designs (i.e., case–crossover and case–time–control) were
derived from published literature, and the following psy-
chotropic medicines were examined: antipsychotics, anx-
iolytics, hypnotics and sedatives, and antidepressants,
stratiﬁed in the two groups selective serotonin reuptake
inhibitors (SSRIs) and other antidepressants. Moreover, in
order to further investigate the effects of frequency of
psychoactive medication exposure on the outcomes of the
case–crossover analysis, the data were also stratiﬁed by the
number of deﬁned daily doses (DDDs) and days of
medication use in the 12 months before the motor vehicle
accident. Three-thousand seven-hundred ﬁfty-two cases
were included in this second part of the case–crossover
analysis. The case–crossover design did not show any sta-
tistically signiﬁcant association between psychotropic
medication exposure and MVA risk [e.g., SSRIs—Adj.
OR = 1.00 (95 % CI: 0.69–1.46); Anxiolytics—Adj.
OR = 0.95 (95 % CI: 0.68–1.31)]. The case–time–control
design only showed a borderline statistically signiﬁcant
increased trafﬁc accident risk in SSRI users [Adj.
OR = 1.16 (95 % CI: 1.01–1.34)]. With respect to the
stratiﬁcations by the number of DDDs and days of medi-
cation use, the analyses showed no increased trafﬁc acci-
dent risk associated with the exposure to the selected
medication groups [e.g., SSRIs, \20 DDDs—Adj.
OR = 0.65 (95 % CI: 0.11–3.87); SSRIs, 16–150 days—
Adj. OR = 0.55 (95 % CI: 0.24–1.24)]. In contrast to the
above-mentioned results, our recent case–control study
found a statistically signiﬁcant association between trafﬁc
accident risk and exposure to anxiolytics [Adj. OR = 1.54
(95 % CI: 1.11–2.15)], and SSRIs [Adj. OR = 2.03 (95 %
CI: 1.31–3.14)]. Case–crossover and case–time–control
analyses produced different results than those of our recent
case–control study (i.e., case–crossover and case–time–
control analyses did not show any statistically signiﬁcant
association whereas the case–control analysis showed an
increased trafﬁc accident risk in anxiolytic and SSRI users).
These divergent results can probably be explained by the
differences in the study designs. Given that the case–
crossover design is only appropriate for short-term expo-
sures and the case–time–control design is an elaboration of
this latter, it can be concluded that, probably, these two
approaches are not the most suitable ones to investigate the
relation between MVA risk and psychotropic medications,
which, on the contrary, are often use chronically.
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Introduction and aim
Driving a motor vehicle is a complex task that involves
several psychomotor and cognitive skills [1]. Some com-
monly prescribed medications can inﬂuence cognitive and
psychomotor functions and, therefore, impair the ability to
drive safely [1, 2].
The risk of experiencing a road trafﬁc accident while
exposed to psychotropic medications has often been esti-
mated by means of pharmacoepidemiological studies, and,
in particular, mainly by case–control and case–crossover
studies [3]. The results of these studies have frequently
shown a positive association between the risk of having a
motor vehicle accident (MVA) and the exposure to some
groups of psychoactive medications (e.g., benzodiazepines,
benzodiazepine-like substances such as zopiclone and
zolpidem, tricyclic antidepressants) [3–5], but, in some
cases, their ﬁndings have been rather controversial. For
instance, in 1997, Hemmelgarn et al. [6] performed a case–
control study which showed that elderly drivers exposed to
long half-life benzodiazepines (BZDs) were signiﬁcantly
associated to the risk of having an MVA within the ﬁrst
week of benzodiazepine use, but, on the contrary, in 1998,
the case–crossover study of Barbone et al. [7] found no
increased trafﬁc accident risk associated to benzodiazepine
use in individuals C65 years old. A similar discrepancy
was also described in the study of Hebert et al. [8] which
showed an increased MVA in case of long half-life BZD
elderly users by applying a case–control approach, but no
association was found by using a case–crossover analysis.
Another example is a recent Dutch case–control study [9]
which reported a statistically signiﬁcant association
between the risk of experiencing a trafﬁc accident and the
exposure to selective serotonin reuptake inhibitors (SSRIs);
however, these results differed from those of Barbone’s
case–crossover study, which found no increased MVA risk
in SSRI users [7].
The divergences in the outcomes of these pharmacoep-
idemiological studies could be explained by the use of
different study designs. Generally speaking, case–control
studies compare cases with an event to controls without the
event, looking for differences in the antecedent exposures
[10]. Case–control studies can be useful when assessing a
wide range of possible causes of a single event as well as
the evaluation of relatively rare events [10, 11]. However,
one of the limitations that are often encountered while
using this study design is the selection of the controls,
which can lead to selection bias and, consequently, incor-
rect conclusions [10, 11]. One possible alternative to the
case–control design is the case–crossover design. The
case–crossover design is an adaptation of the case–control
design in which cases serve as their own controls [12–14].
Because of this peculiarity, the case–crossover design is
immune to the control-selection bias, which, as stated
above, could hamper case–control studies, and it also
controls for stable subject-speciﬁc covariates [12, 14, 15].
However, the case–crossover design is only appropriate to
investigate the effects of incidental exposures on the event
of interest and, therefore, is not suitable to estimate the risk
in people exposed to long-term treatments [7, 15, 16]. If
properly designed and performed, both study designs are
valuable research tools; nevertheless, due to their
assumptions, strengths and limitations, caution has to be
applied when interpreting and comparing their results [11].
Given the fact that the exposure to medications may
change over time [17], it seems reasonable to take the
case–time–control design into consideration, as well. This
type of epidemiologic study design can be regarded as an
extension of the case–crossover design which uses, in
addition to the case group, a series of controls to adjust for
exposures that vary over time [18, 19], and, therefore, it
can offer a useful approach to eliminate the biasing effect
of the aforementioned confounding factor [20].
The aim of this study was to assess the effects of dif-
ferent study designs on the risk estimate. To do so, a case–
crossover and case–time–control study were carried out
and their outcomes were compared with those of a tradi-
tional case–control study design that evaluated the associ-
ation between the risk of having a motor vehicle accident
and the exposure to some psychotropic medication groups
(which are known to be related to driving impairment [3, 5,
7, 21]) [9].
Methods
The case–crossover study, linking police trafﬁc accident
and pharmacy prescription databases, was performed in the
Netherlands, and was focused on a 7-year period (1st
January 2000–31st December 2007).
The data sources, inclusion and exclusion criteria, and
exposure deﬁnition have been described in detail elsewhere
[9]. In brief, a Trusted Third Party (TTP) performed the
linkage between the PHARMO [24], Dutch Trafﬁc and
Navigation Authority (DVS) [25], and Dutch Road
Transport Authority (RDW) [26] databases, which pro-
vided pharmacy prescription data (in particular, the fol-
lowing details were available: dispensing date, the
prescribed dosage, the dispensed quantity and the estimated
duration of use), trafﬁc accident data, and driving license
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123records, respectively. Cases were deﬁned as drivers who
had an MVA attended by the Dutch police during the study
time–frame. Subjects were excluded if they were
B18 years old at the time of the accident (i.e., index date)
and if they tested positive for alcohol or no alcohol test
data were available.
The following medication groups were evaluated: anti-
psychotics (ATC code: N05A), anxiolytics (ATC code:
N05B), hypnotics and sedatives (ATC code: N05C), anti-
depressants stratiﬁed in selective serotonin reuptake
inhibitors (SSRIs) (ATC code: N06AB), and other antide-
pressants [i.e. non-selective monoamine reuptake inhibitors
(ATC code: N06AA), monoamine oxidase A inhibitors
(MAOs) (ATC code: N06AG), other antidepressants (ATC
code: N06AX)].
The case window was deﬁned as the week before the
index date whereas the control window was deﬁned as the
same week 1 year before the index date, to control for
possible seasonal and weather variations which could play
a causal role in trafﬁc accidents.
Exposure was considered to start the day after the dis-
pensing date. Medications dispensed on the MVA day were
not included because it was not possible to determine whe-
ther, in the case window, exposure occurred before or after
the trafﬁc accident. Subjects were considered to be exposed
if the medication was used during the week before the index
date; if the medication exposure ended 2 days before the
index date, the subjects were still considered as exposed.
In order to evaluate the effects of the user type on the
results of the case–crossover design, the study population
was stratiﬁed as follows: (1) Regular users: subjects who
were exposed to a driving impairing medication in the
week before the index date and also used the same medi-
cation in the 6 months before the index date (i.e., subjects
who used a psychotropic medicine on a regular basis dur-
ing the 6 months preceding the trafﬁc accident); (2) Acute
users: subjects who used a driving impairing medication in
the week before the index date, but did not receive any
prescriptions for the same medication in the 6 months
before the initiation of the therapy (i.e., subjects who ini-
tiated their therapy in the week before the MVA, but did
not use this medication in the 6 months before the initiation
of the therapy). In this analysis, subjects were excluded if
their medication history in the 18 months preceding the
index date was not available (Fig. 1).
In order to account for the potential time trends in
psychotropic medication use in the case and control win-
dow [22, 23], a case–time–control analysis was also per-
formed using the same control group that was used in the
case–control study mentioned above [9]. For this investi-
gation, a control group of 18,089 subjects was used. In
brief, the selected controls had to be C19 years old, be in
possession of a driving license and have had no trafﬁc
accident during the study period. Four controls were mat-
ched for each case; the matching was by gender, age within
5 years, zip code, and date of the accident of the corre-
spondent case. The deﬁnitions of the case and control
windows and exposure were the same as reported above.
In order to further investigate the effects of frequency of
psychoactive medication exposure on the outcomes of the
case–crossover analysis, subjects were also stratiﬁed by the
number of deﬁned daily doses (DDDs) (i.e., the total
T0 T1 A
2 days
1 week
B
2 days
T0 T1 T1
T0 T1
1 week
C
2 days
1 week
T0-T 1= 6 months
T1= Traffic accident (index date)
Medication exposure
Fig. 1 Medication exposure in
the case window (a 6-month
period was considered). A Acute
user—Exposed; B Regular
user—Exposed; C Regular
user—Not exposed. It is
important to note that the same
procedure was followed to
assess medication exposure in
the control window (i.e., 1 year
before the index date)
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123number of assumed average maintenance doses per day
that the subjects used in the 12 months preceding the index
date, up to and including the week before the MVA) and
days of medication use in the 12 months before the index
date (i.e., the total number of days of therapy during the
12 months preceding the index date, up to and including
the week before the MVA), with the purpose of having a
broader overview of the subjects’ medication exposures
preceding their trafﬁc accidents. As a consequence, in this
analysis, cases were excluded if their medication history in
the 2 years preceding the index date was not available.
Descriptive statistics was used to describe the demo-
graphic characteristics of the cases and controls as well as
the accident characteristics of the cases.
For the case–crossover and case–time–control designs,
logistic regression analysis was used to estimate odds ratios
(ORs) and 95 % conﬁdence intervals (95 % CIs). The
standard method for matched case–control studies was used
in order to calculate the ORs. The ORs were the measure of
the odds of exposure in the case window versus the control
window; speciﬁcally, medication exposure in the week
before the MVA (case window) was compared with med-
ication exposure during the same week of the control
window, 1 year earlier.
Adjusted ORs were calculated by including exposure to
combination therapy (i.e., concomitant use of at least two
medicines) in the model.
A ‘‘control–crossover’’ analysis was performed similarly
for the selected control group.
The case–time–control ORs were estimated by dividing
the case–crossover ORs from the cases by ‘‘control–
crossover’’ ORs from the controls.
All statistical analyses were performed by using the
statistical package PASW Statistics Version 18.
The study research protocol was reviewed by the Med-
ical Ethics Committee of the University Medical Centre
Groningen (UMCG), the Netherlands, which resulted in the
decision that, according the Dutch Medical Research
Involving Human Subjects Act (WOM), this study did not
need an ethical approval.
Results
Three-thousand seven-hundred eighty-six cases were
included in the ﬁrst part of the case–crossover analysis.
The demographic characteristics of the cases included
the case–crossover study are presented in Table 1.A s
shown in this table, the majority of case population was
male (62.3 %) and the age group 30–60 was the most
represented one (54.2 %).
Table 2 illustrates the characteristics of the case
accidents (i.e., season, weather conditions, time of the
week and time of the day, light conditions, and severity
of the MVA). Accidents were almost equally distributed
during the four seasons, mainly occurred during week -
days, with dry weather conditions, at daylight, between 1
p.m. and 7 p.m., and were mostly either severe or
moderately severe.
Table 1 Demographic charac-
teristics of motor vehicle acci-
dent of the cases
Cases
characteristics
(n = 3,786)
N (%)
Gender
Male 2,360 (62.3)
Female 1,426 (37.7)
Age (years)
\30 1,062 (28.1)
30–60 2,051 (54.2)
C61 673 (17.8)
Table 2 Characteristics of the accidents of motor vehicle accident of
the cases
Accident characteristics (N = 3,786) N (%)
Season
Winter 916 (24.2)
Spring 969 (25.6)
Summer 850 (22.4)
Autumn 1,051 (27.8)
Weather
Dry 3,067 (81.0)
Rain 599 (15.8)
Snow/Hail 45 (1.2)
Fog 49 (1.3)
Hard wind 2 (0.1)
Unknown 24 (0.6)
Week/Weekend
Week day 2,911 (76.9)
Time
1 a.m.–7 a.m. 239 (6.3)
7 a.m.–1 p.m. 1,203 (31.8)
1 p.m.–7 p.m. 1,714 (45.3)
7 p.m.–1 a.m. 630 (16.6)
Light
Daylight 2,741 (72.4)
Dark 826 (21.8)
Dawn 219 (5.8)
Severity
Fatal 24 (0.6)
Severely injured (Hospitalization[24 h) 1,321 (34.9)
Moderately injured (1st aid point or
hospitalization\24 h)
1,421 (37.5)
Slightly injured (Treated on scene) 1,020 (26.9)
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123Table 3 presents the medication exposure of the cases
(regular users and acute users) and controls (regular users
and acute users), in the case and control windows, and the
case–crossover and case–time–control crude and adjusted
ORs for road-trafﬁc accidents related to the exposure to the
selected psychoactive medication groups.
From this table it can be seen that, in the case group,
anxiolytics and SSRIs were the two most used medication
Table 3 Number and percentage of cases and controls exposed to
different psychotropic medication groups, in the case and control
windows, and case–crossover and case–time–control crude and
adjusted ORs (with 95 % conﬁdence intervals) for road-trafﬁc
accidents in different psychotropic medicine group users (ATC codes
in brackets), stratiﬁed by regular users and acute users
Medicine
group
Exposed in
case window (%)
Exposed in
control
window (%)
Case–crossover
crude OR
(95 % CI)
Case–crossover
Adj. OR
(95 % CI)
Case–time–control
crude OR
(95 % CI)
Case–time–control
Adj. OR
(95 % CI)
Antipsychotics (N05A)
Cases (N = 3,786)
Regular users 18 (0.50) 23 (0.60) 0.76 (0.41–1.41) 0.68 (0.34–1.35) 0.94 (0.67–1.32) 0.86 (0.61–1.23)
Acute users 1 (0.02) 1 (0.02) 0.97 (0.06–15.52) 0.97 (0.06–15.52) 1.01 (0.43–2.27) 0.50 (0.33–0.73)
Controls (N = 18,089)
Regular users 91 (0.50) 108 (0.60) 0.81 (0.61–1.07) 0.79 (0.56–1.10) – –
Acute users 2 (0.01) 2 (0.01) 0.96 (0.14–6.84) 1.93 (0.18–21.26) – –
Anxiolitics (N05B)
Cases
Regular users 92 (2.40) 94 (2.50) 0.95 (0.71–1.27) 0.95 (0.68–1.31) 1.09 (0.95–1.25) 1.10 (0.94–1.27)
Acute users 13 (0.34) 11 (0.29) 1.15 (0.51–2.56) 0.97 (0.40–2.33) 1.28 (0.88–1.86) 1.04 (0.70–1.52)
Controls
Regular users 303 (1.70) 335 (1.90) 0.87 (0.75–1.02) 0.86 (0.72–1.03) – –
Acute users 40 (0.22) 43 (0.24) 0.90 (0.58–1.38) 0.93 (0.57–1.53) – –
Hypnotics (N05C)
Cases
Regular users 75 (2.00) 85 (2.20) 0.86 (0.63–1.17) 0.89 (0.63–1.25) 0.98 (0.84–1.13) 0.95 (0.81–1.12)
Acute users 6 (0.16) 11 (0.29) 0.53 (0.20–1.43) 0.39 (0.12–1.24) 0.88 (0.59–1.36) 0.49 (0.28–0.85)
Controls
Regular users 268 (1.50) 293 (1.60) 0.88 (0.75–1.04) 0.94 (0.78–1.12) – –
Acute users 20 (0.11) 32 (0.18) 0.60 (0.34–1.05) 0.80 (0.43–1.46) – –
SSRIs (N06AB)
Cases
Regular users 92 (2.40) 87 (2.30) 1.03 (0.76–1.38) 1.00 (0.69–1.46) 1.26 (1.10–1.41) 1.16 (1.01–1.34)
Acute users 7 (0.18) 5 (0.13) 1.36 (0.43–4.28) 1.29 (0.29–5.79) 1.19 (0.84–1.69) 1.07 (0.60–1.90)
Controls
Regular users 240 (1.30) 281 (1.60) 0.82 (0.69–0.98) 0.86 (0.68–1.09) – –
Acute users 13 (0.07) 11 (0.06) 1.14 (0.51–2.54) 1.21 (0.48–3.05) – –
Other antidepressants
Cases
Regular users 40 (1.10) 45 (1.20) 0.86 (0.56–1.33) 0.88 (0.53–1.46) 1.10 (0.90–1.37) 1.24 (0.98–1.55)
Acute users 3 (0.08) 3 (0.08) 0.97 (0.20–4.81) 0.97 (0.20–4.81) 2.37 (1.25–4.45) 1.76 (1.11–3.01)
Controls
Regular users 143 (0.80) 177 (1.00) 0.78 (0.62–0.97) 0.71 (0.54–0.94) – –
Acute users 6 (0.03) 14 (0.08) 0.41 (0.16–1.08) 0.55 (0.18–1.60) – –
Crude OR Crude odds ratio and corresponding 95 % conﬁdence interval (95 % CI)
Adj. OR Adjusted odds ratio and corresponding 95 % conﬁdence interval (95 % CI) (ORs were adjusted for combination therapy—i.e., the
concomitant use of at least two study medicines)
SSRIs Selective serotonin reuptake inhibitors
Bold: Statistically signiﬁcant
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123classes, with the exception of the control window of acute
users (in this case, hypnotics and anxiolytics were the most
represented classes). On the contrary, in the control group,
the two most represented medication classes were anxio-
lytics and hypnotics, with the exception of the control
window of regular users (in this case, anxiolytics were the
most represented classes, followed by hypnotics and SSRIs
which reported the same percentage of users).
With respect to the crude and adjusted ORs for road-
trafﬁc accidents related to the exposure to the selected
psychoactive medication groups, it can be seen that the
case–crossover analysis did not show any statistically
signiﬁcant association between MVA risk and the exposure
to the selected medications.
After dividing the ORs in the cases by the ORs in the
controls (case–time–control analysis), a signiﬁcant
increased trafﬁc accident risk was obtained for the SSRIs, if
regular users were taken into consideration, whereas a sta-
tistically signiﬁcant association was found between other
antidepressants and MVA risk, if the analysis was restricted
to acute users (see Table 3, last right-hand column).
Three-thousand seven-hundred ﬁfty-two cases were
included in the second part of the case–crossover analysis
(see Table 4—crude and adjusted ORs for road-trafﬁc
Table 4 Number of motor
vehicle accident cases exposed
to different psychotropic
medication groups (ATC codes
in brackets), in the case and
control windows, stratiﬁed by
number of days of use and
number of DDDs, and case–
crossover crude and adjusted
ORs (with 95 % conﬁdence
intervals) for road-trafﬁc
accidents in the year before the
index date (N = 3,752)
Crude OR Crude odds ratio and
corresponding 95 % conﬁdence
interval (95 % CI), Adj. OR
Adjusted odds ratio and
corresponding 95 % conﬁdence
interval (95 % CI) (ORs were
adjusted for combination
therapy—i.e., the concomitant
use of at least two study
medicines), SSRIs Selective
serotonin reuptake inhibitors,
DDDs Deﬁned daily doses
Medicine group Exposed in
case window
Exposed in
control
window
Case–crossover
crude OR
(95 % CI)
Case–crossover
Adj. OR
(95 % CI)
Antipsychotics (N05A)
1–15 days 0 1 – –
16–150 days 1 3 0.32 (0.03–3.11) 0.32 (0.03–3.11)
C151 days 17 19 0.87 (0.45–1.67) 0.79 (0.38–1.64)
\20 DDDs 1 2 0.48 (0.04–5.35) 0.48 (0.04–5.35)
21–150 DDDs 6 9 0.66 (0.23–1.82) 0.48 (0.15–1.61)
C151 DDDs 11 12 0.89 (0.39–2.02) 0.87 (0.35–2.15)
Anxiolytics (N05B)
1–15 days 11 8 1.33 (0.54–3.32) 1.45 (0.52–4.09)
16–150 days 26 37 0.68 (0.41–1.13) 0.59 (0.34–1.05)
C151 days 54 49 1.07 (0.72–1.58) 1.12 (0.73–1.72)
\20 DDDs 22 27 0.79 (0.45–1.39) 0.78 (0.41–1.49)
21–150 DDDs 40 40 0.97 (0.62–1.51) 0.94 (0.59–1.51)
C151 DDDs 29 27 1.04 (0.61–1.76) 1.07 (0.58–1.96)
Hypnotics (N05C)
1–15 days 5 7 0.69 (0.22–2.18) 0.65 (0.18–2.29)
16–150 days 15 28 0.52 (0.28–0.97) 0.57 (0.29–1.14)
C151 days 55 50 1.07 (0.72–1.57) 1.08 (0.71–1.64)
\20 DDDs 6 10 0.58 (0.21–1.60) 0.61 (0.20–1.85)
21–150 DDDs 15 28 0.52 (0.28–0.97) 0.53 (0.27–1.03)
C151 DDDs 54 47 1.11 (0.75–1.65) 1.16 (0.76–1.79)
SSRIs (N06AB)
1–15 days 4 4 0.97 (0.24–3.88) 0.65 (0.11–3.87)
16–150 days 13 25 0.50 (0.26–0.99) 0.55 (0.24–1.24)
C151 days 75 58 1.25 (0.89–1.77) 1.23 (0.80–1.92)
\20 DDDs 4 4 0.97 (0.24–3.88) 0.65 (0.11–3.87)
21–150 DDDs 13 24 0.53 (0.27–1.03) 0.58 (0.25–1.33)
C151 DDDs 75 59 1.23 (0.87–1.74) 1.20 (0.78–1.86)
Other antidepressants
1–15 days 1 2 0.48 (0.04–5.35) 0.97 (0.06–15.50)
16–150 days 7 7 0.97 (0.34–2.77) 0.65 (0.18–2.29)
C151 days 31 34 0.88 (0.54–1.44) 0.93 (0.52–1.65)
\20 DDDs 2 4 0.48 (0.09–2.65) 0.65 (0.11–3.87)
21–150 DDDs 20 19 1.02 (0.53–1.92) 1.04 (0.50–2.15)
C151 DDDs 17 20 0.82 (0.43–1.58) 0.76 (0.35–1.68)
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123accidents in different medication group users, stratiﬁed by
the number of DDDs and days of medication use in the
year before the trafﬁc accident). As can be seen from
Table 4, our analyses showed no increased trafﬁc accident
risk associated with the exposure to the selected medication
groups stratiﬁed by days of use and DDDs in the year
preceding the index date.
In contrast to the above-mentioned results, our recent
case–control study found a statistically signiﬁcant associ-
ation between trafﬁc accident risk and exposure to anxio-
lytics [Adj. OR = 1.54 (95 % CI: 1.11–2.15)], and SSRIs
[Adj. OR = 2.03 (95 % CI: 1.31–3.14)] [9].
Discussion and conclusions
To the best of our knowledge, this is one of the few studies
that evaluated and highlighted the possible impact of dif-
ferent epidemiologic study designs (i.e., case–control,
case–crossover, and case–time–control) on the association
between MVA risks and psychotropic medication exposure
in the same study population.
The results of our case–crossover study did not show
any signiﬁcant increase in MVA risk associated with the
exposure to the selected psychotropic medicine groups
[e.g., Regular user stratiﬁcation: Anxiolytics: Adj.
OR = 0.95 (95 % CI: 0.68–1.31); SSRIs: Adj. OR = 1.00
(95 % CI: 0.69–1.46)]. Stratiﬁcations according to the
number of days and DDDs used in the previous year were
consistent with the above-mentioned ﬁndings, and, in
particular, did not show any effects of exposure frequency
on the risk of experiencing an MVA [e.g., 1–15 day
stratiﬁcation: Anxiolytics: Adj. OR = 1.45 (95 % CI:
0.52–4.09); SSRIs: Adj. OR = 0.65 (95 % CI: 0.11–3.87)].
Therefore, if compared to our recent pharmacoepidemio-
logical study [9], it can be observed that the current case–
crossover analysis produced different results than those of
the case–control analysis, which actually found a statisti-
cally signiﬁcant association between trafﬁc accident risk
and exposure to anxiolytics and SSRIs [Anxiolytics: Adj.
OR = 1.54 (95 % CI: 1.11–2.15); SSRIs: Adj. OR = 2.03
(95 % CI: 1.31–3.14)—all exposed individuals].
Lastly, the outcomes of the case–time–control analysis
showed a borderline statistically signiﬁcant increased risk
only in SSRI users, in the stratiﬁcation referred to regular
users [Adj. OR = 1.16 (95 % CI: 1.01–1.34)], whereas the
acute user stratiﬁcation only showed a statistically signiﬁ-
cant association between MVA risk and other antidepres-
sant users [Adj. OR = 1.76 (95 % CI: 1.11–3.01)].
Therefore, it can be speculated that, in this case, the ﬁnd-
ings of the case–time–control analysis only partially sup-
ported the outcomes of the case–control one.
The discrepancies between the outcomes of the case–
control and case–crossover studies could be attributed to
the choice of study design. The case–crossover design is a
commonly used scientiﬁc method to investigate whether a
certain event was triggered by something unusual that
happened just before the event itself [14]. The case–
crossover is a matched case–control study, but it only
involves cases and each case serves as its own control [14].
Because of this peculiarity, the case–crossover design
controls for stable subject-speciﬁc covariates and it over-
comes control selection bias [13]. However, this type of
design requires that the exposures are brief and their effects
transient [10, 13]. Considering that psychotropic medica-
tions are often used on a regular and chronic basis [8, 17,
27], it can be speculated that, in the present study, one of
the most important assumptions of the case–crossover
design was not met, and, therefore, the choice of this study
design was probably not appropriate. To be more precise, it
is relevant to point out that the case–crossover odds ratio is
estimated by the ratio of the number of cases exposed only
during the case window to the number of cases exposed
only during the control window (i.e., ratio of discordant
pairs). Given that only discordant pairs contribute to the
estimation of the odds ratio in matched analyses, if the
exposure does not change in a systematic way over time, it
is likely to face a loss of precision because there is a lack of
discordant pairs as exposure becomes more homogeneous,
and eventually reduces the power of the study [13, 22, 29,
30]. Therefore, based on the above-mentioned consider-
ations, it can be conceivably hypothesised that the case–
crossover analysis should be limited to intermittent users of
the selected medication groups. However, it is important to
note that, in the current study, this restriction led to a
consistent loss of cases and, even if the ORs calculated for
this speciﬁc group of users were more similar to the ORs
obtained by applying the case–control technique, it can be
speculated that, as stated before, our study did not have
adequate statistical power to detect reliably the association
between incidental psychotropic medication users and
MVA risks [10, 11].
Stratifying the data according to the number of DDDs
and days of use in the previous year did not support the
associations that were shown in the case–control study
either. With respect to the DDD, a possible explanation for
this might be that, since the deﬁned daily dose is a unit of
measurement and does not necessarily reﬂect the recom-
mended or prescribed daily dose [28], the actual doses used
by our study population could have been considerably
different from the recommended DDD; therefore, perhaps
this stratiﬁcation was not appropriate and led to a mis-
classiﬁcation of our medication users.
With respect to the days of use, it is difﬁcult to explain
the study outcomes, but, as stated above, they could be
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which might have resulted in a lack of statistical power to
address the issue of the association between the risk of
experiencing an MVA while incidentally exposed to psy-
choactive medications [10, 11].
Besides the points reported above, there could also be
other possible explanations for the discrepancies among the
ﬁndings of the two designs that were used. As some authors
have also pointed out [8, 13, 22, 29, 30], possible reasons
for different results between case–crossover and case–
control studies may be related to selection bias of the con-
trol–person–time (i.e., our selected control–person–time did
not properly represent the population-time that generated
the cases due to, for example, possible divergences in the
driving patterns between the case and control times), con-
founding by indication (no information was available on
what medical condition the psychotropic medications were
prescribed for, and, consequently, we could not account for
the confounding effect of the disease) different effects of
the medication at different points in time (e.g., different
estimates in relation to therapy duration and/or prior
exposures [31]), time-varying within-subject confounding
factors (e.g., ﬂuctuations in disease severity, co-morbidities,
etc.), and time trend bias (i.e., changes in the prescribing
patterns of the medications of interest).
With regard to the case–time–control analysis, our study
only showed a positive association between MVA risk and
SSRI users [Adj. OR = 1.16 (95 % CI: 1.01–1.34)], in the
regular user group, and other antidepressant users [Adj.
OR = 1.76 (95 % CI: 1.11–3.01)], in the acute user strat-
iﬁcation, but, in contrast to our earlier ﬁndings, no evi-
dence of an increased trafﬁc accident risk associated with
anxiolytics was detected [Adj. OR = 1.10 (0.94–1.27)].
The reason for the discrepant outcomes of this analysis is
not clear, but it might also be related to the choice of the
study design. The current case–time–control study was
performed to remove bias due to time trends from the case–
crossover estimate [22, 23], and, as suggested by Suissa
[18], to possibly control for confounding by indication.
However, since the case–time–control design can be seen
as an elaboration of the case–crossover design [30] (i.e., it
corresponds to the division of the case–crossover matched-
pair odds ratio by a ‘‘control–crossover’’ (time–control)
matched-pair odds ratio [32]), our ﬁndings could have been
limited by the same shortcomings as those of the case–
crossover approach (e.g., selection bias in the control–time
window, within-person confounding, time-varying within-
subject confounding factors, etc.). Additionally, our case–
time–control design might have had the same difﬁculty
addressing chronic exposures and chronic effects as our
case–crossover analysis. In particular, if the exposure was
chronic, few controls were available with discordant
exposures in different time periods, and, as well as the
case–crossover design, our resultant case–time–control
analysis could have been hampered by a poor statistical
power compared to a conventional study [32]. Moreover,
since the case–time–control design requires a traditional
control group, our study, and, consequently, its results
could have been hampered by the same limitations as the
case–control design, as well (e.g., selection bias in the
collection process of the control group, between-person
confounding, higher complexity due to the necessity of a
control group, etc.) [18, 22, 30]. Lastly, as Greenland
argued [32], on the one hand, our case–time–control design
could have been a helpful tool to adjust for time trends in
measured exposures, but, on the other hand, if unmeasured
confounders and/or carryover effects were present, new
biases could have been introduced. As a consequence, the
problem of confounding by indication would not have been
solved and our ﬁnal results could have been either more or
less confounded than those obtained by the case–control
and case–crossover analyses [32].
Our study supports the observations of Hebert et al. [8],
who also compared the results of a case–control study to
those of a case–crossover study using the same database to
determine the association between BZDs and the risk of
MVAs. In that study, the case–control approach demon-
strated an increased MVA risk associated with the use of
long-acting BZDs whereas the case–crossover approach
applied to all cases did not show any association. The
authors concluded that the differences among the ﬁndings
of these studies could have derived from intrinsic differ-
ences between the two designs, and that, in particular, a
lack of intermittency of exposure could have altered the
point estimates of their case–crossover analysis [8].
Although the differences between the study populations
should be considered as a possible cause of divergent
ﬁndings, the previously mentioned assumption could also
clarify the discrepancies between the outcomes of Hem-
melgarn et al.’s case–control study [6] and those of Bar-
bone et al.’s case–crossover study [7] which, respectively,
showed a statistically signiﬁcant association between BZD
exposure and trafﬁc accident in older adults and no evi-
dence that BZDs increased trafﬁc accident risks in elderly
patients.
Lastly, this hypothesis could also explain the contradic-
tory ﬁndings between our case–control study on SSRIs and
increased MVA risk [9] and Barbone’s case–crossover
outcomes which, in contrast to our research, found no
increased risk of road-trafﬁc accidents in users of SSRIs [7].
In conclusion, our investigation has shown that different
study designs seemed to give different answers to the same
research hypothesis, in the same population (i.e., the out-
comes of the case–crossover and case–time–control anal-
yses were not in line with the outcomes of the case–control
analysis, which showed an increased trafﬁc accident risk in
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123anxiolytic and SSRI users). Considering that every study
design has different design-speciﬁc assumptions, and
strengths and limitations, it could be assumed that our
analyses actually tested distinctive causal hypotheses and
focused on different aspects of psychoactive medication
use and MVA risk [8, 22, 29]. As a consequence, it seems
reasonable to conclude that each pharmacoepidemiological
design may be appropriate only in certain settings and
under speciﬁc assumptions [22], and, therefore, if possible,
multiple designs and analyses should be used to investigate
the different aspects of factors that can play a role in trafﬁc
safety while driving under the inﬂuence of psychotropic
medications.
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